Method of assessing a subject for abnormal kidney function
US-9733259-B2 · Aug 15, 2017 · US
Method for identifying an agent for treating abnormal kidney function
US10191067B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10191067-B2 |
| Application number | US-201715632753-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 26, 2017 |
| Priority date | Sep 21, 2010 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of identifying an agent for treating or reducing the risk of developing abnormal kidney function, which is defined as an albumin creatinine ratio (ACR) of 3.5 or more, the method comprising: (i) contacting cells expressing at least one biomarker, wherein said at least one biomarker is CD5 antigen like, with a putative agent; and (ii) comparing expression and/or levels of the at least one biomarker in the cells prior to contact with the putative agent to expression and/or levels of the at least one biomarker in the cells after contact with the putative agent; wherein a change in the level or expression identifies the agent as an agent for treating or reducing the risk of developing abnormal kidney function. 2. The method according to claim 1 , wherein the cells are contacted with the putative agent in vitro. 3. The method according to claim 2 , wherein the cells are contacted with the putative agent in a cell culture or cell line. 4. The method according to claim 1 , wherein the cells are contacted with the putative agent in vivo. 5. The method according to claim 4 , wherein the cells are contacted with the putative agent in an animal model. 6. The method according to claim 1 , wherein the step of comparing expression and/or levels of the at least one biomarker in the cells comprises the step of measuring the concentration of a peptide fragment of the at least one biomarker. 7. The method according to claim 6 , wherein the concentration of the peptide fragment is measured using mass spectrometry.
Assignees
Inventors
Classifications
for hyperglycaemia, e.g. antidiabetics · CPC title
Complement proteins, e.g. anaphylatoxin, C3a, C5a · CPC title
involving peroxidase · CPC title
- G01N33/6893Primary
related to diseases not provided for elsewhere · CPC title
acting on hydrogen peroxide as acceptor (1.11) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10191067B2 cover?
- Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.
- Who is the assignee on this patent?
- Proteomics Int Pty Ltd, Univ Western Australia
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6893. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).